Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005-2009

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 5, 2011, Pages 457-463

  Mahic, Milada ^a   Skurtveit, Svetlana ^a,b   Selmer, Randi ^a   Rønning, Marit ^a   Furu, Kari ^a,c  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Adalimumab; Etanercept; Minimum refill; Norway; Prescription drug use

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

AGE DISTRIBUTION; AMBULATORY CARE; ARTICLE; DATA BASE; DRUG USE; HUMAN; INCIDENCE; NORWAY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE;

ANTIBODIES, MONOCLONAL; DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; MALE; NORWAY; PREVALENCE; RECEPTORS, TUMOR NECROSIS FACTOR; SEX FACTORS; TIME FACTORS;

EID: 79955138676     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2091     Document Type: Article

References (19)

1. Gibbons LJ, Hyrich KL.Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.BioDrugs 2009;23(2):111-124.
2. Saini R, Tutrone WD, Weinberg JM.Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.Curr Pharm Des 2005;11(2):273-280.
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al.Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.Arthritis Rheum 2008;58 (2 Suppl):S126-S135.
4. Arora T, Padaki R, Liu L, et al.Differences in binding and effector functions between classes of TNF antagonists.Cytokine 2009;45(2):124-131.
5. Gladman DD.Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis.Nat Clin Pract Rheumatol 2008;4(10):510-511.
6. Furu K.Establishment of the nationwide Norwegian Prescription Database (NorPD) - new opportunities for research in pharmacoepidemiology in Norway.Nor J Epidemiol 2008;18:129-136.
7. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2010, 2009.
8. Caetano PA, Lam JM, Morgan SG.Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization.Clin Ther 2006;28(9):1411-1424.
9. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM.Primary non-compliance with prescribed medication in primary care.Br Med J 1993;307(6908):846-848.
10. Kvien TK, Uhlig T, Odegard S, Heiberg MS.Epidemiological aspects of rheumatoid arthritis: the sex ratio.Ann N Y Acad Sci 2006;1069:212-222.
11. Ramsburg KL.Rheumatoid arthritis.Am J Nurs 2000;100(11):40-43.
12. Braathen LR, Botten G, Bjerkedal T.Prevalence of psoriasis in Norway.Acta Derm Venereol Suppl (Stockh) 1989;142:5-8.
13. Bernklev T, Jahnsen J, Schulz T, et al.Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis.Eur J Gastroenterol Hepatol 2005;17(10):1037-1045.
14. Henriksen M, Jahnsen J, Lygren I, et al.Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study).Scand J Gastroenterol 2007;42(5):602-610.
15. Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL.Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register.Rheumatology (Oxford) 2010;49(4):697-705.
16. Symmons DP, Silman AJ.The world of biologics.Lupus 2006;15(3):122-126.
17. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF, Jr., Griffin MR.Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.Med Care 2007;45 (10 Suppl 2):S66-S76.
18. Crum NF, Lederman ER, Wallace MR.Infections associated with tumor necrosis factor-alpha antagonists.Medicine (Baltimore) 2005;84(5):291-302.
19. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT.The Nordic countries as a cohort for pharmacoepidemiological research.Basic Clin Pharmacol Toxicol 2010;106(2):86-94.